Jimena Davis, Ph.D.

Senior Scientist I

Jimena joined MetrumRG in June 2023 as a Senior Scientist I. She earned her PhD in Applied and Computational Mathematics from North Carolina State University. She brings with her over 15 years of mathematical modeling and computational biology experience. Jimena spent 4 years at the US EPA as a Mathematical Statistician focused on uncertainty quantification of linked exposure-to-effects models for human health risk assessments. She then applied her mathematical modeling skills in various roles at Syngenta, including modeling biological pathways to support gene candidate discovery for plant traits and breeding in various crops. Jimena enjoys modeling complex biological systems to tackle challenges that humans face, and she’s looking forward to collaborating on solutions that will inform biomedical decisions in drug development programs.

 

 

Recent publications by this scientist

Symbolic PBPK-PDE Modeling using Open-Source Julia Tools.

December 6, 2024

Presented at ACoP 2024. The poster introduces a framework for developing physiologically based pharmacokinetic (PBPK) models that incorporate partial differential equations (PDEs) to account for spatial drug distribution, using open-source Julia tools. This approach simplifies the integration of spatial components into PBPK models, demonstrated through a case study on naphthalene diffusion, and is applicable to various pharmacometric models requiring spatial considerations, such as topical, inhaled, and antitumor therapies.

Download PDF

How to Make a Salad? Rethinking Pharmacometric/QSP Model Composition using Open-Source Julia Tools.

December 6, 2024

Presented at ACoP 2024. The poster presents a framework for pharmacometric and quantitative systems pharmacology (QSP) model composition using open-source Julia tools. This framework allows for seamless integration and reuse of independent model components, facilitating the creation of complex models from simpler ones, and demonstrating applications in drug interactions, viral dynamics, and bispecific antibody modeling.

Download PDF

Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-targeted Loncastuximab Tesirine With Epcoritamab in B-cell Lymphoma

October 1, 2024

Presented at ACCP Annual Meeting 2024, this poster highlights a combination QSP model for Loncastuximab Tesirine and Epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), predicting potential anti-tumor synergies in proposed clinical trials.

Download PDF